-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Rilparencel in Type 1 Diabetes (Juvenile Diabetes)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rilparencel in Type 1 Diabetes (Juvenile Diabetes) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rilparencel in Type 1 Diabetes (Juvenile Diabetes) Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ART-27.13 in Cancer Anorexia-Cachexia Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ART-27.13 in Cancer Anorexia-Cachexia Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ART-27.13 in Cancer Anorexia-Cachexia Syndrome Drug Details: ART-27.13 (NEO-1940, AZD-1940) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NEO-100 in Meningioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NEO-100 in Meningioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NEO-100 in MeningiomaDrug Details:NEO-100 is under development for the treatment of glioblastoma multiforme, and...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Talazoparib in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talazoparib in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talazoparib in Triple-Negative Breast Cancer (TNBC) Drug Details: Talazoparib (Talzenna,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talazoparib in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talazoparib in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talazoparib in Metastatic Breast Cancer Drug Details: Talazoparib (Talzenna, Tarzena) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talazoparib in Urethral Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talazoparib in Urethral Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talazoparib in Urethral Cancer Drug Details: Talazoparib (Talzenna, Tarzena) is an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talazoparib in Metastatic Transitional (Urothelial) Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talazoparib in Metastatic Transitional (Urothelial) Tract Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talazoparib in Metastatic Transitional (Urothelial) Tract Cancer Drug...